袁群生;李雪梅;
YUAN Qun-sheng;LI Xue-mei;Department of Nephrology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院肾内科

摘要(Abstract)：

2009年改善全球肾脏病预后组织(kidney disease:improving global outcomes,KDIGO)发布了关于慢性肾脏病矿物质及骨异常(chronic kidney disease-mineral and bone disorder,CKD-MBD)的诊断、评估、预防和治疗的临床实践指南,为广大临床工作者对CKD-MBD的认识及诊疗提供了详细的指导意见。但指南缺少针对临床终点事件的随机对照研究(randomized control trial,RCT)证据,故其证据质量不高。随着此后多项RCT研究和前瞻性队列研究结果的公布,KDIGO工作组经过对相关新证据的评估和充分讨论,于2017年6月对该指南进行了选择性更新,主要涉及CKD-MBD中骨病的诊断及钙、磷和甲状旁腺素的管理等。本文就主要的更新内容进行解读,揭示其临床意义。
The Kidney Disease: Improving Global Outcomes( KDIGO) Clinical Practice Guideline for the Diagnosis,Evaluation,Prevention,and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder( CKD-MBD)was originally published in 2009,which assists practitioners in clinical diagnosis,prevention,and treatment of CKD-MBD. However,the Guideline Work Group acknowledged the lack of sufficient evidence for the base of recommendations. The Guideline included specific research recommendations to encourage investigators to help fill the gaps and bolster the evidence base. With the accumulation of related results of multiple randomized and controlled trials and prospective cohort studies since 2009, 2017 KDIGO Clinical Practice Guideline for the Diagnosis,Evaluation,Prevention,and Treatment of CKD-MBD represents a selective update on the prior guideline published in 2009. Specifically,the topic areas for which updated recommendations are issued include the diagnosis of bone abnormalities in CKD-MBD,treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance,treatment of parathyroid hormone abnormalities in CKD-MBD,and so on. A total of 12 recommendations were reevaluated and updated based on new data. This report interprets the updates on 2017 KDIGO ClinicalPractice Guideline for the Diagnosis,Evaluation,Prevention,and Treatment of CKD-MBD and describes the results of these proceedings,which highlights the significance of KDIGO CKD-MBD guideline in clinical practice.

关键词(KeyWords)： 指南,更新;慢性肾脏病;矿物质及骨异常;骨密度
guideline,update;chronic kidney disease;mineral and bone disorder;bone mineral density

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 袁群生;李雪梅;
YUAN Qun-sheng;LI Xue-mei;Department of Nephrology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

参考文献(References)：

• [1]Kidney disease:improving global outcomes(KDIGO)CKD-MBD work group.KDIGO clinical practice guideline for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J].Kidney Int Suppl,2009,76:S1-S130.
• [2]Kidney disease:improving global outcomes(KDIGO)CKD-MBD update work group.KDIGO 2017 clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J].Kidney Int Suppl,2017,7:1-59.
• [3]Alem AM,Sherrard DJ,Gillen DL,et al.Increased risk of hip fracture among patients with end-stage renal disease[J].Kidney Int,2000,58:396-399.
• [4]Nickolas TL,Mc Mahon DJ,Shane E.Relationship between moderate to severe kidney disease and hip fracture in the United States[J].J Am Soc Nephrol,2006,17:3223-3232.
• [5]Mittalhenkle A,Gillen DL,Stehman-Breen CO.Increased risk of mortality associated with hip fracture in the dialysis population[J].Am J Kidney Dis,2004,44:672-679.
• [6]Tentori F,Mc Cullough K,Kilpatrick RD,et al.High rates of death and hospitalization follow bone fracture among hemodialysis patients[J].Kidney Int,2014,85:166-173.
• [7]Iimori S,Mori Y,Akita W,et al.Diagnostic usefulness of bonemineral density and biochemical markers of bone turnover inpredicting fracture in CKD stage 5D patients-a single-centercohort study[J].Nephrol Dial Transplant,2012,27:345-351.
• [8]West SL,Lok CE,Langsetmo L,et al.Bone mineral density predictsfractures in chronic kidney disease[J].J Bone Miner Res,2015,30:913-919.
• [9]Haghverdi F,Mortaji S,Soltani P,et al.Effect of raloxifene onparathyroid hormone in osteopenic and osteoporoticpostmenopausal women with chronic kidney disease stage 5[J].Iran J Kidney Dis,2014,8:461-466.
• [10]Jamal SA,Ljunggren O,Stehman-Breen C,et al.Effects ofdenosumab on fracture and bone mineral density by level of kidneyfunction[J].J Bone Miner Res,2011,26:1829-1835.
• [11]EVOLVE Trial Investigators,Chertow GM,Block GA,et al.Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis[J].N Engl J Med,2012,367:2482-2494.
• [12]Block GA,Kilpatrick RD,Lowe KA,et al.CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization inpatients on hemodialysis[J].Clin J Am Soc Nephrol,2013,8:2132-2140.
• [13]Chartsrisak K,Vipattawat K,Assanatham M,et al.Mineral metabolism and outcomes in chronic kidney disease stage 2-4patients[J].BMC Nephrol,2013,14:14-20.
• [14]Eddington H,Hoefield R,Sinha S,et al.Serum phosphate and mortality inpatients with chronic kidney disease[J].Clin J Am Soc Nephrol,2010,5:2251-2257.
• [15]Fouque D,Roth H,Pelletier S,et al.Control of mineral metabolism and bone disease in haemodialysis patients:which optimal targets?[J].Nephrol Dial Transplant,2013,28:360-367.
• [16]Gross P,Six I,Kamel S,et al.Vascular toxicity of phosphate in chronic kidney disease:beyond vascular calcification[J].Circ J,2014,78:2339-2346.
• [17]Hill KM,Martin BR,Wastney ME,et al.Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease[J].Kidney Int,2013,83:959-966.
• [18]Block GA,Wheeler DC,Persky MS,et al.Effects of phosphate binders in moderate CKD[J].J Am Soc Nephrol,2012,23:1407-1415.
• [19]Di Iorio B,Bellasi A,Russo D,et al.Mortality in kidney disease patients treated with phosphate binders:a randomized study[J].Clin J Am Soc Nephrol,2012,7:487-493.
• [20]Di Iorio B,Molony D,Bell C,et al.Sevelamer versus calcium carbonate in incident hemodialysis patients:results of an openlabel 24-month randomized clinical trial[J].Am JKidney Dis,2013,62:771-778.
• [21]Jamal SA,Vandermeer B,Raggi P,et al.Effect of calciumbased versus non-calcium-based phosphate binders on mortality inpatients with chronic kidney disease:an updated systematic reviewand meta-analysis[J].Lancet,2013,382:1268-1277.
• [22]Karavetian M,de Vries N,Elzein H,et al.Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients,Lebanon[J].Patient Educ Couns,2015,98:1116-1122.
• [23]Floege J,Kim J,Ireland E,et al.Serum i PTH,calcium and phosphate,and the risk of mortality in a European haemodialysis population[J].Nephrol Dial Transplant,2011,26:1948-1955.
• [24]Spiegel DM,Brady K.Calcium balance in normal individuals and in patients with chronic kidney disease on low-and highcalcium diets[J].Kidney Int,2012,81:1116-1122.
• [25]St Peter WL,Li Q,Liu J,et al.Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization,2004 through 2006[J].Clin J Am Soc Nephrol,2009,4:354-360.
• [26]Denburg MR,Tsampalieros AK,de Boer IH,et al.Mineral metabolism and cortical volumetric bone mineral density inchildhood chronic kidney disease[J].J Clin Endocrinol Metab,2013,98:1930-1938.
• [27]Ok E,Asci G,Bayraktaroglu S,et al.Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis[J].J Am Soc Nephrol,2016,27:2475-2486.
• [28]Spasovski G,Gelev S,Masin-Spasovska J,et al.Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium[J].Bone,2007,41:698-703.
• [29]Thadhani R,Appelbaum E,Pritchett Y,et al.Vitamin Dtherapy and cardiac structure and function in patients with chronic kidney disease:the PRIMO randomized controlled trial[J].JAMA,2012,307:674-684.
• [30]Li XH,Feng L,Yang ZH,et al.The effect of active vitamin d on cardiovascular outcomes in predialysis chronic kidney diseases:a systematic review and meta-analysis[J].Nephrology(Carlton),2015,20:706-714.
• [31]Parfey PS,Drüeke TB,Block GA,et al.The effects of cinacalcet in older and younger patients on hemodialysis:the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events(EVOLVE)trial[J].Clin J Am Soc Nephrol,2015,10:791-799.
• [32]Parfrey PS,Chertow GM,Block GA,et al.The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet:the EVOLVE trial[J].J Clin Endocrinol Metab,2013,98:4834-4844.
• [33]Behets GJ,Spasovski G,Sterling LR,et al.Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism[J].Kidney Int,2015,87:846-856.
• [34]Raggi P,Chertow GM,Torres PU,et al.The advance study:a randomized study to evaluate the effects of cinacalcet plus low-dosevitamin D on vascular calcification in patients on hemodialysis[J].Nephrol Dial Transplant,2011,26:1327-1339.